Bioengineered Protein Drug Market Research Report By Therapeutic Area (Oncology, Immunology, Metabolic Disorders, Neurological Disorders, Cardiovascular Diseases), By Type of Bioengineered Protein (Monoclonal Antibodies, Fusion Proteins, Enzymes, Hormones, Growth Factors), By Administration Route (Intravenous, Subcutaneous, Intramuscular, Intraperitoneal, Topical), By Expression System (Mammalian Cell Culture, Bacterial Expression, Yeast Expression, Plant Expression, Insect Cell Expression) and By Region - Forecast to 2032

Bioengineered Protein Drug Market Overview:

As per MRFR analysis, the bioengineered protein drug market size was estimated at 298.92 (USD Billion) in 2022. The bioengineered protein drug market industry is expected to grow from 326.22 (USD Billion) in 2023 to 716.4 (USD Billion) by 2032. The bioengineered protein drug market CAGR (growth rate) is expected to be around 9.13% during the forecast period (2024-2032).

Key Bioengineered Protein Drug Market Trends Highlighted

The bioengineered protein drug market is primarily driven by the rising prevalence of chronic diseases, advancements in biotechnology, and the increasing adoption of personalized medicine. As protein-based therapies offer targeted and effective treatment options for diseases like cancer, diabetes, and autoimmune disorders, there is a growing demand for these drugs.

Key opportunities in the bioengineered protein drug market include the development of novel protein-based therapies for unmet medical needs. The exploration of new delivery technologies, such as nanotechnology and antibody-drug conjugates, offers the potential to enhance drug efficacy and reduce side effects. Additionally, growing emphasis on precision medicine presents opportunities to develop customized therapies tailored to individual patients' genetic profiles.

Recent trends in the bioengineered protein drug market include the increasing adoption of monoclonal antibodies for a wide range of therapeutic applications. Another notable trend is the emergence of biosimilars, which are like existing biologics but offered at a lower cost, contributing to increased accessibility and affordability of these drugs.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Bioengineered Protein Drug Market Drivers

Rising Prevalence of Chronic Diseases

One of the major drivers of the Bioengineered Protein Drug Market is the increasing prevalence of chronic diseases, including cancer, diabetes, and various cardiovascular diseases. These ailments require continuous treatment, and bioengineered protein drugs offer focused and efficient therapies that can help patients achieve better results.

Owing to the ability of bioengineered protein drugs to up- and down-regulate specific biological pathways, as well as to target the disease-causing mechanisms, they have a substantial potential for the treatment of multifaceted and incapacitating ailments. Since the population is growing older, the incidence of chronic diseases keeps increasing, which means that the demand for bioengineered protein drugs is expected to witness a steady rise.

Advancements in Biotechnology

Biotechnology is the area in which rapid advancements are evident. One of the crucial components of the development of this sector is the substantial progress in protein and genetic engineering. Therefore, currently, scientists can create and produce protein drugs being extremely specific and potent, focusing on the proteins and pathways, which cause certain diseases. Moreover, the possibility to engineer proteins with better stability, solubility, and bioavailability has also been a significant contributor to the growth of the market in bioengineered protein drugs.

Government Support and Funding

Governments across the world has recognized the potential of bioengineered protein drugs in healthcare to improve healthcare outcomes and ease the burden from the chronic diseases with people are suffering. Financial support is given to the research institutions and pharmaceutical companies to rapidly develop and launch them in the market.

Hence, the availability of funds empowered the researchers to discover novel targets and develop innovative bioengineered protein drugs, which thereby fueled the Bioengineered Protein Drug Market growth.

Bioengineered Protein Drug Market Segment Insights:

Bioengineered Protein Drug Market Therapeutic Area Insights

The therapeutic area segment is one of the central aspects to consider when investigating the Bioengineered Protein Drug Market landscape. Among the most prominent therapeutic areas that are spurring growth in the market and deserve attention in any analysis are oncology, immunology, metabolic disorders, neurological disorders, and cardiovascular diseases.

Oncology is the therapeutic area in which the development of treatments has been most affected by bioengineered protein drugs. The oncology segment is expected to reach a value of USD 267.4 billion by 2024, representing a significant share of the total market revenue. The growing demand for products of this type can be associated with the impressive progress in bioengineered protein drugs used for cancer treatment because of their effectiveness and minimal side effects.

Immunology is the segment with the value estimated at USD 125.6 billion by 2024, and this already demonstrates the interest of patients and the potential of the market. The use of protein-based therapies has enabled significant progress in managing a variety of immune-related diseases, including such common issues as autoimmune conditions, allergies, and various sources of inflammation.

Bioengineered proteins are also considered promising for the treatment of disorders, such as metabolic conditions, including diabetes and obesity. The use of drugs focused on these specific conditions is expected to result in a segment value of USD 67.2 billion by 2024 due to the growth of the prevalence of such conditions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Bioengineered Protein Drug Market Type of Bioengineered Protein Insights

The bioengineered protein drug market is segmented by type of bioengineered protein into monoclonal antibodies, fusion proteins, enzymes, hormones, and growth factors. Monoclonal antibodies are expected to hold the largest market share in 2023, due to their high specificity and affinity for target antigens, as well as the ability to modulate immune responses.

Fusion proteins is expected to be the fastest-growing segment, due to the ability to combine the functionalities of two or more proteins, offering superior functions and decreased immunogenicity. Enzymes are expected to have a significant market share, as they play a critical role in several biological procedures, while hormones and growth factors is expected to have a constant market share, as they play a critical role in the regulation of growth, development, and metabolism. This is due to the increasing prevalence of chronic disorders, the growing adoption of customized treatments, and the advancements in bioengineering technology.

Bioengineered Protein Drug Market Administration Route Insights

The Bioengineered Protein Drug Market is segmented by administration route into intravenous, subcutaneous, intramuscular, intraperitoneal, and topical. Intravenous administration route held the largest market share in 2023 and is projected to continue its dominance throughout the forecast period.

The growth of this segment can be attributed to the increasing adoption of biologics and the convenience of intravenous administration. Bioengineered proteins are often administered intravenously due to their complex structure and high molecular weight, which can make oral or subcutaneous administration challenging.

Intravenous administration allows for precise dosing and immediate delivery to the bloodstream. However, intravenous administration requires trained healthcare professionals and can be associated with discomfort or side effects at the injection site.

Bioengineered Protein Drug Market Expression System Insights

The expression system segment is categorized based on the type of host organism used for protein production. In 2023, the mammalian cell culture segment held the largest market share due to its ability to produce complex proteins with high yields and post-translational modifications.

However, the bacterial expression segment is expected to witness significant growth over the forecast period (2023-2032), owing to its cost-effectiveness and scalability. Yeast expression, plant expression, and insect cell expression are other notable segments within the Expression segment.

Yeast Expression offers advantages in terms of scalability and low production costs, while Plant Expression provides the potential for producing large quantities of proteins in a cost-effective manner. This growth can be attributed to the increasing prevalence of chronic diseases, technological advancements in protein engineering, and rising demand for personalized medicine.

Bioengineered Protein Drug Market Regional Insights

The Bioengineered Protein Drug Market is segmented into North America, Europe, APAC, South America, and MEA. North America dominates the market, capturing over 40% of the market share in 2023 due to the presence of major pharmaceutical companies and advanced healthcare infrastructure. Europe holds the second-largest share, driven by government initiatives and increasing investments in research and development.

APAC is expected to witness the fastest growth over the forecast period, owing to rising healthcare expenditure, growing awareness of bioengineered protein drugs, and expanding patient population. South America and MEA are expected to contribute a smaller share to the overall market due to limited healthcare infrastructure and lower adoption rates.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Bioengineered Protein Drug Market Key Players and Competitive Insights:

Major players in the market are continuously focusing on research and development to expand their product portfolio and cater to unmet medical needs. For instance, in May 2023, Amgen announced the acquisition of ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases and cancer, to enhance its portfolio of inflammation and oncology therapies.

Leading players are also engaging in partnerships and collaborations to combine their expertise and capabilities to develop novel treatments. In March 2023, Eli Lilly and Company and Incyte entered a strategic collaboration to develop and commercialize baricitinib, a JAK1/2 inhibitor, for the treatment of various immune-mediated diseases, including rheumatoid arthritis and atopic dermatitis.

Amgen, Inc. is a leading player in the bioengineered protein drug market. The company has a strong focus on research and innovation and has a diverse portfolio of bioengineered protein drugs. Amgen's key products include Enbrel, Prolia, and Neulasta. The company has a broad global presence, and its products are commercialized in over 100 countries. Amgen is committed to developing innovative treatments that improve the lives of patients with serious diseases.

Roche Holding AG is a global healthcare company with a strong focus on oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The company has a track record of developing and commercializing innovative bioengineered protein drugs. Roche's key products include Avastin, Herceptin, and Rituxan. The company has a broad global presence, and its products are commercialized in over 100 countries. Roche is committed to developing innovative treatments that improve the lives of patients with serious diseases.

Key Companies in the Bioengineered Protein Drug Market Include:

• Eli Lilly and Company


• Johnson & Johnson


• AstraZeneca


• Roche


• Gilead Sciences


• Sanofi


• Biogen


• Pfizer


• Bristol Myers Squibb


• Novartis


• Celgene


• AbbVie


• Merck & Co.


• Amgen


• Vertex Pharmaceuticals

Bioengineered Protein Drug Market Developments

The Bioengineered Protein Drug Market is poised to witness substantial growth over the forecast period of 2024-2032. In 2023, the market was valued at approximately USD 326.22 billion, and it is projected to reach a valuation of USD 716.4 billion by 2032, exhibiting a CAGR of 9.13%. This growth can be attributed to factors such as the rising prevalence of chronic diseases, increasing adoption of personalized medicine, technological advancements in protein engineering, and supportive government policies.

Recent news developments include the approval of novel bioengineered protein drugs for various indications, strategic collaborations between pharmaceutical companies, and the expansion of manufacturing capacities to meet growing demand.

Bioengineered Protein Drug Market Segmentation Insights

Bioengineered Protein Drug Market Therapeutic Area Outlook

• Oncology


• Immunology


• Metabolic Disorders


• Neurological Disorders


• Cardiovascular Diseases

Bioengineered Protein Drug Market Type of Bioengineered Protein Outlook

• Monoclonal Antibodies


• Fusion Proteins


• Enzymes


• Hormones


• Growth Factors

Bioengineered Protein Drug Market Administration Route Outlook

• Intravenous


• Subcutaneous


• Intramuscular


• Intraperitoneal


• Topical

Bioengineered Protein Drug Market Expression System Outlook

• Mammalian Cell Culture


• Bacterial Expression


• Yeast Expression


• Plant Expression


• Insect Cell Expression

Bioengineered Protein Drug Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa